Optimising experimental research in respiratory diseases: an ERS statement - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Respiratory Journal Année : 2018

Optimising experimental research in respiratory diseases: an ERS statement

Martin Stampfli
  • Fonction : Auteur
Stefan Uhlig
  • Fonction : Auteur
Eric White
  • Fonction : Auteur
Martin Witzenrath
  • Fonction : Auteur
Bruno Crestani
  • Fonction : Auteur
Oliver Eickelberg
Heinz Fehrenbach
  • Fonction : Auteur
Andreas Guenther
  • Fonction : Auteur
Gisli Jenkins
  • Fonction : Auteur
Guy Joos
Bernard Maitre
  • Fonction : Auteur
  • PersonId : 838119
Ulrich  A. Maus
  • Fonction : Auteur
Petra Reinhold
  • Fonction : Auteur
Juanita H.J. Vernooy
  • Fonction : Auteur
Luca Richeldi
  • Fonction : Auteur


Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective. The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research. The task force statement addresses general issues of experimental research (ethics, species, sex, age, ex vivo and in vitro models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension. The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.

Dates et versions

hal-01996906 , version 1 (28-01-2019)



Philippe Bonniaud, Aurélie Fabre, Nelly Frossard, Christophe Guignabert, Mark Inman, et al.. Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51 (5), pp.1702133. ⟨10.1183/13993003.02133-2017⟩. ⟨hal-01996906⟩
311 Consultations
0 Téléchargements



Gmail Facebook Twitter LinkedIn More